These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 10223932

  • 1. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.
    Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1999 May; 43(5):1177-82. PubMed ID: 10223932
    [Abstract] [Full Text] [Related]

  • 2. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
    Nagai K, Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2740-6. PubMed ID: 10991854
    [Abstract] [Full Text] [Related]

  • 3. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [Abstract] [Full Text] [Related]

  • 4. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K, Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC.
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [Abstract] [Full Text] [Related]

  • 5. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

  • 6. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ.
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [Abstract] [Full Text] [Related]

  • 7. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA, Kelly LM, Hoellman DB, Ednie LM, Clark CL, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
    Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
    [Abstract] [Full Text] [Related]

  • 10. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K, Credito K, Pankuch GA, Lin G, Bozdogan B, McGhee P, Dewasse B, Choi DR, Ryu JM, Appelbaum PC.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [Abstract] [Full Text] [Related]

  • 11. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS, Fisher LM.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
    Taba H, Kusano N.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
    [Abstract] [Full Text] [Related]

  • 14. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
    Browne FA, Bozdogan B, Clark C, Kelly LM, Ednie L, Kosowska K, Dewasse B, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3815-24. PubMed ID: 14638489
    [Abstract] [Full Text] [Related]

  • 15. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ, Ambler JE, Fisher LM.
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [Abstract] [Full Text] [Related]

  • 16. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
    Pan XS, Fisher LM.
    Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
    [Abstract] [Full Text] [Related]

  • 17. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.
    Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L.
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2760-4. PubMed ID: 9124836
    [Abstract] [Full Text] [Related]

  • 18. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
    Pestova E, Beyer R, Cianciotto NP, Noskin GA, Peterson LR.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
    [Abstract] [Full Text] [Related]

  • 19. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR, Tapsall JW, White PA.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [Abstract] [Full Text] [Related]

  • 20. Primary targets of fluoroquinolones in Streptococcus pneumoniae.
    Fukuda H, Hiramatsu K.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):410-2. PubMed ID: 9925547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.